No more than 15 authors can be listed.Please ensure the authors are listed in the right order.If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.
Chronic end-stage lung diseases are associated with progressive impairment of functional exercise capacity due to ventilatory limitation, gas exchange abnormalities, and increased symptom burden. The six-minute walk test (6MWT) is widely used to assess functional capacity; however, its feasibility may be limited in certain clinical and infrastructural settings. The three-minute walk test (3MWT) has been proposed as a shorter alternative, but its ability to reflect functional capacity and disease severity requires further evaluation. This study aimed to compare the 3MWT and 6MWT in assessing functional capacity in patients with chronic end-stage lung disease and to examine their association with disease severity, pulmonary function, and diffusing capacity for carbon monoxide (DLCO).
This analytical cross-sectional study was conducted in a tertiary care hospital and included 89 adult patients with chronic end-stage lung disease. All participants underwent both the 3MWT and 6MWT on separate days using standardized protocols. Physiological parameters, Borg dyspnoea and fatigue scores, spirometry, and DLCO were recorded before and after each test. Walking distances and functional performance were compared, and correlations with post-test pulmonary function parameters were analysed.
The 6MWT elicited significantly greater physiological responses, symptom burden, and walking distance compared to the 3MWT (p<0.001). Both tests demonstrated consistent declines in performance with increasing modified Medical Research Council (mMRC) dyspnoea grades. Strong positive correlations were observed between post-test spirometric parameters and DLCO values following both tests (p<0.001). Although of lower magnitude, the 3MWT produced measurable and clinically relevant functional outcomes.
The three-minute walk test is a feasible and reliable tool for assessing functional capacity and disease severity in patients with chronic end-stage lung disease. While the 6MWT remains superior in eliciting greater physiological stress, the 3MWT serves as a practical alternative in settings where the 6MWT is not feasible.